Adial Pharmaceuticals (NASDAQ:ADIL) Announces Earnings Results

Adial Pharmaceuticals (NASDAQ:ADIL) released its earnings results on Thursday. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.01, FiscalAI reports.

Adial Pharmaceuticals Stock Up 1.9%

Shares of NASDAQ:ADIL traded up $0.01 during trading on Friday, reaching $0.33. 357,273 shares of the company traded hands, compared to its average volume of 429,715. Adial Pharmaceuticals has a 52 week low of $0.22 and a 52 week high of $1.30. The firm has a market capitalization of $7.10 million, a PE ratio of -0.43 and a beta of 1.32. The company’s 50 day moving average is $0.36 and its two-hundred day moving average is $0.43.

Analyst Ratings Changes

ADIL has been the topic of a number of recent research reports. Zacks Research cut Adial Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 20th. Maxim Group raised shares of Adial Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a research note on Tuesday, September 30th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Adial Pharmaceuticals in a report on Wednesday, October 8th. Finally, Wall Street Zen raised Adial Pharmaceuticals to a “sell” rating in a research note on Saturday, July 26th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Adial Pharmaceuticals has an average rating of “Hold” and an average price target of $1.50.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.